Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Nanoscope Therapeutics Texas Maryland Denmark Finland France Germany Netherlands Sweden United Kingdom

MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of the retinaRESTORE is the first randomized, controlled trial of a mutation-agnostic gene therapy for a genetic diseaseNanoscope anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both RP and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for GA due to AMD.

Investor Contact:
Argot Partners
212-600-1902
[e-mail]

Logo - https://mma.prnewswire.com/media/1333752/Nanoscope_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/nanoscope-therapeutics-announces-positive-top-line-results-from-randomized-controlled-trial-of-mco-010-for-retinitis-pigmentosa-302098525.html